Flexaril (Cyclobenzaprine) Dosage
The standard dosage of Flexaril (cyclobenzaprine) is 5 mg three times daily, with the option to increase to 10 mg three times daily based on individual response, but treatment should not exceed 2-3 weeks. 1
Standard Dosing Recommendations
For most patients, start with 5 mg three times daily. This lower dose provides equivalent efficacy to 10 mg three times daily while significantly reducing sedation and other adverse effects 2. The 5 mg dose demonstrated:
- Comparable pain relief and functional improvement to 10 mg dosing
- Lower incidence of somnolence (reported as adverse event in 0.8% vs 7.3% with 10 mg)
- Similar rates of treatment response (88% mild improvement at 3 days, 93% at 7 days)
If inadequate response after several days, the dose may be increased to 10 mg three times daily (maximum recommended dose) 1.
Special Population Dosing
Elderly Patients
Start with 5 mg once daily and titrate slowly upward 1. The elderly face increased risks due to:
- Higher plasma concentrations from altered pharmacokinetics
- Greater susceptibility to CNS adverse events (hallucinations, confusion)
- Increased risk of cardiac events and falls
- Enhanced anticholinergic effects (urinary retention, constipation, dry mouth)
Hepatic Impairment
Mild hepatic impairment: Start with 5 mg and titrate slowly upward 1
Moderate to severe hepatic impairment: Use is NOT recommended 1. Plasma concentrations are significantly increased in hepatic dysfunction, and these patients are more susceptible to sedating effects.
Duration of Treatment
Limit treatment to 2-3 weeks maximum 1. Evidence for efficacy beyond this timeframe is lacking. With long-term use:
- Withdrawal symptoms (malaise, nausea, headache) may occur for 2-4 days after discontinuation 3
- Taper over 2-3 weeks if discontinuing after prolonged use to prevent withdrawal 3
Extended-Release Formulation
An extended-release formulation (cyclobenzaprine ER) is available at 15 mg or 30 mg once daily 4. This provides:
- Similar efficacy to immediate-release formulation
- Reduced daytime drowsiness compared to immediate-release
- Lower reported somnolence (0.8-1.6% vs 7.3% with immediate-release)
- Peak concentrations at 6-8 hours, providing sustained plasma levels
Critical Safety Considerations
Absolute Contraindications
- MAO inhibitor use (within 14 days): Life-threatening interactions including hyperpyretic crisis, severe seizures 1
- Acute recovery phase of myocardial infarction
- Arrhythmias, heart block, conduction disturbances, heart failure
- Hyperthyroidism
Important Drug Interactions
- Enhances effects of alcohol, barbiturates, and CNS depressants 1
- Tramadol: May enhance seizure risk 1
- Blocks antihypertensive effects of guanethidine
Common Adverse Effects (Dose-Related)
- Somnolence (most common)
- Dry mouth
- Dizziness
- Constipation
- Urinary retention
- Confusion (especially in elderly)
Clinical Context
Cyclobenzaprine is NOT a first-line agent for most musculoskeletal conditions. The 2021 SPAQI consensus recommends holding cyclobenzaprine on the day of surgery due to interactions with sedatives and anesthetic agents 3. For acute musculoskeletal pain, evidence shows cyclobenzaprine provides modest benefit but is associated with significant CNS adverse effects 5, 6.
The 5 mg three times daily regimen offers the best balance of efficacy and tolerability for patients requiring muscle relaxant therapy, with efficacy independent of sedation 2. Adding ibuprofen to cyclobenzaprine 5 mg provides no additional benefit over cyclobenzaprine alone 7.